A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
Indications Bladder cancer; Non-small cell lung cancer; Skin cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms China Extension Study
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

27 Sep 2022 Status changed from active, no longer recruiting to completed..
18 May 2022 Planned End Date changed from 5 Jul 2022 to 12 Sep 2022.
15 Mar 2022 Planned End Date changed from 7 Mar 2022 to 5 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight